Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 13/20 | 0.44 |
| ▸ | CETP | P11597 | 1/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.40 |
| ▸ | NSD2 | O96028 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5096953 | 0.87 | GPR119 (0.43) | GPR119TGFBR1ALDH1A1 | |
| SCHEMBL5097027 | 0.81 | PDE4A (0.42) | GPR119TGFBR1 | |
| SCHEMBL5091008 | 0.80 | HTT (0.40) | GPR119TGFBR1ALDH1A1 | |
| SCHEMBL5090892 | 0.74 | MAPT (0.37) | ALDH1A1 | |
| SCHEMBL4519627 | 0.73 | GPR119 (0.47) | GPR119IRAK4 | |
| SCHEMBL5090995 | 0.72 | HSD17B1 (0.46) | — | |
| SCHEMBL201583 | 0.72 | GPR119 (0.64) | GPR119 | |
| SCHEMBL3487620 | 0.70 | GPR119 (0.72) | GPR119 | |
| SCHEMBL6808688 | 0.70 | GPR119 (0.51) | GPR119JAK2JAK3PTK2IRAK4 | |
| SCHEMBL14012602 | 0.69 | HSD17B1 (0.43) | IRAK4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306111-A1 | TRICYCLIC DELTA- OPIOID MODULATORS | CARSON JOHN R | 2008-12-11 | — | — | US | disclosed |
| US-20080306111-A1 | TRICYCLIC DELTA- OPIOID MODULATORS | CARSON JOHN R | 2008-12-11 | — | — | US | disclosed |
| US-20080306111-A1 | TRICYCLIC DELTA- OPIOID MODULATORS | CARSON JOHN R | 2008-12-11 | — | — | US | disclosed |
| EP-1836196-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006069275-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-29 | — | — | WO | disclosed |
| US-20060135522-A1 | Tricyclic delta-opioid modulators | CARSON JOHN R | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135522-A1 | Tricyclic delta-opioid modulators | OPRD1, OPRK1, OPRL1 | GPR119 540/4885CETP 1048/4885TGFBR1 771/4885 |
| US-20080306111-A1 | TRICYCLIC DELTA- OPIOID MODULATORS | OPRD1, OPRK1, OPRL1 | GPR119 540/4885CETP 1048/4885TGFBR1 771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.